Abstract
Hsp90 is a potential target for the treatment of cancer. Curcumin is a natural product used to prevent and treat cancer. 4-(4-Hydroxy-3-methoxybenzyl) curcumin (C086), a 4-arylmethyl curcumin analogue, showed lead-like properties. Western blot analyses and molecular docking study supported C086 as an Hsp90 inhibitor. Subsequently, C086 analogues were designed, synthesized and evaluated. These compounds showed increased antiproliferative activity against SKBr3 and MCF-7 breast cancer cells. The most promising compounds 7 and 10 (IC50=1.66µM and 0.509µM) were 5- fold and 17-fold better than C086 (IC50=8.55µM) against SkBr3 cell, respectively. Her2 degradation and Hsp70 induction were observed upon administration of selected 4-arylmethyl curcumin analgues, suggesting that these compounds exerted their activity through Hsp90 inhibition.
Keywords: 4-Arylmethyl curcumin analogue, Breast cancer, Curcumin, Hsp90, Hsp90 inhibitors, Molecular docking.
Letters in Drug Design & Discovery
Title:Synthesis and Evaluation of 4-arylmethyl Curcumin Analgues as Potent Hsp90 Inhibitors
Volume: 11 Issue: 8
Author(s): Yang Liu, Min Ye, Qundan Wu, Lixian Wu and Jianhua Xu
Affiliation:
Keywords: 4-Arylmethyl curcumin analogue, Breast cancer, Curcumin, Hsp90, Hsp90 inhibitors, Molecular docking.
Abstract: Hsp90 is a potential target for the treatment of cancer. Curcumin is a natural product used to prevent and treat cancer. 4-(4-Hydroxy-3-methoxybenzyl) curcumin (C086), a 4-arylmethyl curcumin analogue, showed lead-like properties. Western blot analyses and molecular docking study supported C086 as an Hsp90 inhibitor. Subsequently, C086 analogues were designed, synthesized and evaluated. These compounds showed increased antiproliferative activity against SKBr3 and MCF-7 breast cancer cells. The most promising compounds 7 and 10 (IC50=1.66µM and 0.509µM) were 5- fold and 17-fold better than C086 (IC50=8.55µM) against SkBr3 cell, respectively. Her2 degradation and Hsp70 induction were observed upon administration of selected 4-arylmethyl curcumin analgues, suggesting that these compounds exerted their activity through Hsp90 inhibition.
Export Options
About this article
Cite this article as:
Liu Yang, Ye Min, Wu Qundan, Wu Lixian and Xu Jianhua, Synthesis and Evaluation of 4-arylmethyl Curcumin Analgues as Potent Hsp90 Inhibitors, Letters in Drug Design & Discovery 2014; 11 (8) . https://dx.doi.org/10.2174/1570180811666140512221037
DOI https://dx.doi.org/10.2174/1570180811666140512221037 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Potential Use of Hormone-Based Therapeutics for the Treatment of Alzheimers Disease
Current Alzheimer Research Cannabinoid Receptors as Target for Treatment of Osteoporosis: A Tale of Two Therapies
Current Neuropharmacology Novel Research Strategies of Benzimidazole Derivatives: A Review
Mini-Reviews in Medicinal Chemistry Targeting Heat Shock Proteins in Tauopathies
Current Alzheimer Research Antioxidant, Antimicrobial Activity and Medicinal Properties of Grewia asiatica L.
Medicinal Chemistry Specific Targeting of Akt Kinase Isoforms: Taking the Precise Path for Prevention and Treatment of Cancer
Current Drug Targets Tumor-dependent Effects of Proteoglycans and Various Glycosaminoglycan Synthesizing Enzymes and Sulfotransferases on Patients’ Outcome
Current Cancer Drug Targets Probable Mechanisms Involved in Immunotoxin Mediated Capillary Leak Syndrome (CLS) and Recently Developed Countering Strategies
Current Molecular Medicine Structure-Function Relationships of Plasminogen Activator Inhibitor-1 and Its Potential as a Therapeutic Agent
Current Drug Targets Bioactive Herbal Alkaloids as Anti-Infective Agents
Anti-Infective Agents Beyond Oncolytic Virotherapy: Replication-Competent Retrovirus Vectors for Selective and Stable Transduction of Tumors
Current Gene Therapy Structure-Activity Relationships of Flavonoids
Current Organic Chemistry Marine Derived Anticancer Drugs Targeting Microtubule
Recent Patents on Anti-Cancer Drug Discovery Recent Advances on Liquid Chromatographic and Mass Spectrometric Analysis of Selective Estrogen Receptor Modulators (SERMs) in Biological Fluids
Current Chromatography An In Silico Appraisal of Azoic and Disulphide Derivatives for Anticancer Activity Against HPV E6 Oncoprotein to Medicate Cervical Cancer
Combinatorial Chemistry & High Throughput Screening The Pharmaceutical Potential of Histone Deacetylase Inhibitors
Current Pharmaceutical Design Quantitative Structure-Activity Relationship Studies: Understanding the Mechanism of Tyrosine Kinase Inhibition
Current Enzyme Inhibition Chemokines and Their Receptors: Potential Therapeutic Targets for Bone Cancer Pain
Current Pharmaceutical Design Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis
Recent Patents on Biomedical Engineering (Discontinued) Long Noncoding RNA MALAT1: Insights into its Biogenesis and Implications in Human Disease
Current Pharmaceutical Design